Physician profile
Ryan Houk
NPI 1053640003
$3,825.54
in general payments reported to CMS, 2019-2025
22 companies · $845 in 2025
The $845 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $256 · 2021: $435 · 2022: $112 · 2023: $748 · 2024: $791 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,364 · Education: $19.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,364.12 |
| Education | $19.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $767.69 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $658.18 | 2019-2025 | |
| Amgen INC. | $393.59 | 2019-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $326.64 | 2022-2025 | Onpattro |
| Pfizer INC. | $256.12 | 2023-2025 | |
| Ge Healthcare | $246.47 | 2021 | |
| Kestra Medical Technology Services, INC. | $191.00 | 2023 | Assure Wcd |
| Edwards Lifesciences Corporation | $175.30 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $162.56 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $132.20 | 2023-2025 | Farxiga |
| Boston Scientific Corporation | $90.57 | 2023 | Watchman Flx |
| Cvrx, INC. | $68.75 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $55.58 | 2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.33 | 2019-2021 | |
| Bridgebio Pharma, INC. | $48.28 | 2025 | Attruby |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $41.98 | 2024 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.65 | 2022-2024 | Lifevest |
| Philips North America LLC | $34.88 | 2024 | (Cm9) Amb Mon & Diag Und |
| Novo Nordisk INC | $25.25 | 2025 | Wegovy |
| Medtronic, INC. | $24.23 | 2023 | Micra |
| Medtronic Vascular, INC. | $23.41 | 2020 | |
| Bracco Diagnostics INC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Houk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.